With regard to Health Canada’s Special Access Program (SAP) that considers requests for access to drugs that are otherwise unavailable to Canadians from medical practitioners to treat serious or life-threatening conditions: (a) what is the aggregate number of applications that have been received by the SAP in the 2015, 2016, and 2017 calendar years; (b) of all SAP applications received in the 2015, 2016, and 2017 calendar years, what is the number of repeat applications for the same drug or health product; (c) for drugs that have received multiple requests in the 2015, 2016, and 2017 calendar years, what are the drug names and the number of requests they have each received; (d) what is the total number of SAP applications that have been approved in the 2015, 2016, and 2017 calendar years; (e) what is the total number of SAP applications that have been rejected in the 2015, 2016, and 2017 calendar years; (f) what are the alphabetized names of all drugs and health products that have been approved by the SAP program in the 2015, 2016, and 2017 calendar years; (g) what are the alphabetized names of all drugs and health products that have been rejected by the SAP program in the 2015, 2016, and 2017 calendar years; (h) how many times has the procedures manual that assessors refer to in administration of the SAP been updated and what are these updates for the 2015, 2016, and 2017 calendar years; (i) what are the measures undertaken by Health Canada to ensure its workers have a good understanding of the medical conditions they're reviewing as part of SAP applications; and (j) what is the aggregate cost of administering the SAP to the Government of Canada for the 2016 fiscal year?
In the House of Commons on June 5th, 2018. See this statement in context.